Related Experiment Video

Updated: May 14, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells

Karam Kim1, Sungkwan An, Hwa Jun Cha

  • 1Molecular-Targeted Drug Research Center, Konkuk University, Gwangjin-gu, Seoul 143-701;

Oncology Letters
|February 20, 2013
PubMed

Insights

Lenalidomide shows anticancer effects in non-small cell lung cancer (NSCLC) by reducing cell viability. It alters gene expression, upregulating apoptosis activators like BID and FOS, while downregulating NKX2-1.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death globally.
  • Current NSCLC therapies have limited efficacy.
  • Lenalidomide, approved for other conditions, shows potential as an NSCLC treatment.

Purpose of the Study:

  • To investigate the molecular mechanisms of lenalidomide's anticancer effects in NSCLC.
  • To elucidate the cellular events triggered by lenalidomide in NSCLC.

Main Methods:

  • Utilized NSCLC cell lines to assess lenalidomide's impact on cell viability.
  • Performed array-based gene expression analysis to identify regulated genes.
  • Focused on genes involved in apoptosis and cell proliferation.

Main Results:

  • Lenalidomide demonstrated a concentration-dependent reduction in NSCLC cell viability.
  • Gene expression analysis revealed modulation of key genes: BH3-interacting domain death agonist (BID), v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS), and NK2 homeobox1 (NKX2-1).
  • Lenalidomide upregulated apoptosis activators BID and FOS, and downregulated NKX2-1, a marker for NSCLC.

Conclusions:

  • Lenalidomide exerts direct antiproliferative effects on NSCLC cells.
  • These effects are mediated by altering the expression of genes critical for cell proliferation and apoptosis.
  • Lenalidomide represents a potential therapeutic agent for NSCLC, warranting further investigation into its molecular action.
Keywords:
cell growth inhibitiongene expression profileslenalidomidenon-small cell lung carcinoma cell

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...